Can Torsemide Cause Hyperparathyroidism?
Yes, torsemide and other loop diuretics can cause secondary hyperparathyroidism by increasing urinary calcium loss, which leads to compensatory PTH elevation.
Mechanism of Action
Loop diuretics like torsemide act on the thick ascending limb of the loop of Henle, where they inhibit the Na+/K+/2Cl- carrier system 1. This mechanism directly increases urinary excretion of calcium, creating a hypercalciuric state 2, 3. The resulting calcium loss triggers a physiological cascade:
- Increased urinary calcium excretion → hypocalcemia or low-normal serum calcium
- Hypocalcemia stimulates parathyroid glands → elevated PTH secretion
- Chronic PTH elevation → secondary hyperparathyroidism with potential bone consequences
The 2025 French Endocrinology Society guidelines explicitly identify hypercalciuria as a mechanism that can stimulate excessive PTH production and lead to parathyroid gland hyperplasia 4.
Clinical Evidence
The evidence for loop diuretic-induced hyperparathyroidism is substantial:
In a study of 275 CKD patients, furosemide (another loop diuretic) was a strong independent predictor of secondary hyperparathyroidism, even after adjusting for kidney function and calcium excretion rates 5. Patients on furosemide had significantly higher rates of PTH >65 pg/mL compared to those on thiazide diuretics.
Loop diuretics alter the diurnal rhythm of PTH secretion, causing steep increases in both urinary calcium and plasma PTH levels. Mean 24-hour PTH concentrations nearly doubled (8.5 vs 4.4 mmol/L) in patients receiving loop diuretics compared to placebo 6.
Chronic loop diuretic use in infants has resulted in severe secondary hyperparathyroidism with PTH levels exceeding 500 pg/mL, causing bone disease that required calcimimetic therapy for reversal 7.
Contrast with Thiazide Diuretics
Thiazide diuretics have the opposite effect 8, 9:
- They increase tubular calcium reabsorption
- Reduce urinary calcium excretion (hypocalciuric effect)
- May suppress PTH secretion
- Can actually unmask or worsen primary hyperparathyroidism by raising serum calcium
The 2013 AACE guidelines note that thiazide diuretics decrease renal calcium loss and may predispose to hypercalcemia in patients with mild primary hyperparathyroidism 8.
Clinical Implications and Monitoring
When prescribing torsemide, particularly for chronic use:
Monitor calcium homeostasis: Check serum calcium, PTH, and consider 24-hour urinary calcium, especially in patients with:
- Chronic kidney disease (stages 3-5)
- Long-term diuretic requirements
- Pre-existing bone disease
- Premature infants with bronchopulmonary dysplasia
Risk is highest with:
- Prolonged therapy duration
- Higher doses
- Concurrent CKD (which independently causes secondary hyperparathyroidism) 10
- Inadequate calcium/vitamin D intake
Consider thiazide alternatives when appropriate, as they provide renal calcium retention rather than wasting 3.
Management Approach
If secondary hyperparathyroidism develops during torsemide therapy 4:
- Assess calcium intake: Ensure adequate dietary calcium (1200-1500 mg/day) and vitamin D sufficiency (25-OH vitamin D >30 ng/mL)
- Consider calcium supplementation: 600 mg twice daily can normalize PTH in cases of insufficient intake 11
- Evaluate need for continued loop diuretic: Can the patient be switched to a thiazide if appropriate for their indication?
- In refractory cases: Active vitamin D (calcitriol) or calcimimetics may be required 7
The FDA label for torsemide warns about electrolyte abnormalities including hypocalcemia 1, though it does not explicitly mention hyperparathyroidism as a consequence. However, the mechanistic pathway through calcium wasting is well-established in the literature 3, 6, 5.
Bottom line: Torsemide causes hypercalciuria that can lead to secondary hyperparathyroidism, particularly with chronic use. This is a class effect of loop diuretics and represents a clinically significant adverse effect requiring monitoring and potential intervention.